Zobrazeno 1 - 10
of 218
pro vyhledávání: '"Patrizia Nanni"'
Autor:
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Arianna Palladini, Stefania Angelicola, Chiara Cappello, Olga Maria Pittino, Patrizia Nanni, Pier-Luigi Lollini
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 16, p 12963 (2023)
Cancer vaccines are increasingly being studied as a possible strategy to prevent and treat cancers. While several prophylactic vaccines for virus-caused cancers are approved and efficiently used worldwide, the development of therapeutic cancer vaccin
Externí odkaz:
https://doaj.org/article/8ded555a69794ee0b5e08c117ab222f2
Autor:
Veronica Giusti, Francesca Ruzzi, Lorena Landuzzi, Marianna L. Ianzano, Roberta Laranga, Elena Nironi, Laura Scalambra, Giordano Nicoletti, Carla De Giovanni, Martina Olivero, Maddalena Arigoni, Raffaele Calogero, Patrizia Nanni, Arianna Palladini, Pier-Luigi Lollini
Publikováno v:
Oncogenesis, Vol 10, Iss 11, Pp 1-12 (2021)
Abstract HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In this work, we studied cell lines derived from two transgenic mammary tumors driven by human HER2 that showed different dynamics of HER2 status. MamBo89HE
Externí odkaz:
https://doaj.org/article/b560bd2ffc044642b16dd92b9b06a0fa
Autor:
Lorena Landuzzi, Arianna Palladini, Claudio Ceccarelli, Sofia Asioli, Giordano Nicoletti, Veronica Giusti, Francesca Ruzzi, Marianna L. Ianzano, Laura Scalambra, Roberta Laranga, Tania Balboni, Maddalena Arigoni, Martina Olivero, Raffaele A. Calogero, Carla De Giovanni, Massimiliano Dall’Ora, Enrico Di Oto, Donatella Santini, Maria Pia Foschini, Maria Cristina Cucchi, Simone Zanotti, Mario Taffurelli, Patrizia Nanni, Pier-Luigi Lollini
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
Abstract We established patient-derived xenografts (PDX) from human primary breast cancers and studied whether stability or progressive events occurred during long-term in vivo passages (up to 4 years) in severely immunodeficient mice. While most PDX
Externí odkaz:
https://doaj.org/article/59a0895a37d34757859e7e9b853a7ad6
Autor:
Patrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, Alberto Righi, Giordano Nicoletti, Camilla Cristalli, Michela Pasello, Alessandro Parra, Marianna Carrabotta, Manuela Ferracin, Arianna Palladini, Marianna L. Ianzano, Veronica Giusti, Francesca Ruzzi, Mauro Magnani, Davide Maria Donati, Piero Picci, Pier-Luigi Lollini, Katia Scotlandi
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Standard therapy of osteosarcoma (OS) and Ewing sarcoma (EW) rests on cytotoxic regimes, which are largely unsuccessful in advanced patients. Preclinical models are needed to break this impasse. A panel of patient-derived xenografts (PDX) wa
Externí odkaz:
https://doaj.org/article/520fd06572ac4ed78a2083b0e3a1fa0d
Autor:
Carla De Giovanni, Patrizia Nanni, Lorena Landuzzi, Marianna L. Ianzano, Giordano Nicoletti, Stefania Croci, Arianna Palladini, Pier-Luigi Lollini
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Insulin-like Growth Factor Receptor-1 (IGF1R) system sustains the genesis of rhabdomyosarcoma through IGF2 autocrine overexpression. While several IGF1R-targeted strategies have been investigated to interphere with rhabdomyosarcom
Externí odkaz:
https://doaj.org/article/98c06761c44e458a8f112936ff488f59
Publikováno v:
BMC Immunology, Vol 19, Iss 1, Pp 1-6 (2018)
Abstract Cancer immunoprevention is based on the fact that a functioning immune system controls tumor onset and development in humans and animals, thus leading to the idea that the enhancement of immune responses in healthy individuals could effectiv
Externí odkaz:
https://doaj.org/article/b3b8be3c9db44811b539b373832a0824
Autor:
Carla De Giovanni, Lorena Landuzzi, Arianna Palladini, Giordano Nicoletti, Patrizia Nanni, Pier-Luigi Lollini
Publikováno v:
Cells, Vol 10, Iss 7, p 1808 (2021)
Rhabdomyosarcomas (RMS) are tumors of the skeletal muscle lineage. Two main features allow for distinction between subtypes: morphology and presence/absence of a translocation between the PAX3 (or PAX7) and FOXO1 genes. The two main subtypes are fusi
Externí odkaz:
https://doaj.org/article/12e4369e2c9b4f35a2d73d4015d16707
Autor:
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini
Publikováno v:
Cancers, Vol 13, Iss 2, p 309 (2021)
Immune checkpoint inhibitors (ICIs) improve the survival of patients with multiple types of cancer. However, low response rates and atypical responses limit their success in clinical applications. The paradoxical acceleration of tumor growth after tr
Externí odkaz:
https://doaj.org/article/05a2f19a6e9f488fa5cf0a5322861170
Autor:
Valerio Leoni, Andrea Vannini, Valentina Gatta, Julie Rambaldi, Mara Sanapo, Catia Barboni, Anna Zaghini, Patrizia Nanni, Pier-Luigi Lollini, Costanza Casiraghi, Gabriella Campadelli-Fiume
Publikováno v:
PLoS Pathogens, Vol 14, Iss 8, p e1007209 (2018)
Oncolytic herpes simplex viruses (oHSVs) showed efficacy in clinical trials and practice. Most of them gain cancer-specificity from deletions/mutations in genes that counteract the host response, and grow selectively in cancer cells defective in anti
Externí odkaz:
https://doaj.org/article/941a02ea5ec54fb1bb91d83ff00a6408
Autor:
Patrizia Nanni, Carla De Giovanni, Alessia Burocchi, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Marianna Lucia Ianzano, Ivano Arioli, Mario P. Colombo, Pier-Luigi Lollini
Publikováno v:
OncoImmunology, Vol 7, Iss 8 (2018)
This study evaluated the effects of combining an OX40 agonistic antibody (aOX40) with a cell vaccine targeting HER2/neu, called “Triplex”. Such HER2/neu cell vaccine included two biological adjuvants (interleukin 12 (IL12) and allogeneic histocom
Externí odkaz:
https://doaj.org/article/8eadcd7678204624bb8b5facf4a2c8b7